



Murine Anti-Factor VIII

Clone GMA-8014

Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor (vWF). Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca^{2+} . Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8014 (also known as 3G6)¹ recognizes the C2 domain of FVIII. The antibody strongly inhibits FVIII activation and is unaffected by the presence of vWF or phospholipid membranes.¹ GMA-8014 detects FVIII C2 domain by surface plasmon resonance,^{2,3} and is suitable for ELISA and bio-layer interferometry pairing experiments.

Description


Antibody Source:	mouse monoclonal, IgG _{2b}
Antigen Species Bound:	human
Specificity:	FVIII C2 domain
Immunogen:	B-domain deleted recombinant human FVIII

Formulation and Storage

Purity:	IgG purified by protein G affinity chromatography from serum-free cell culture supernatant.
Product Formulation:	Lyophilized from a ≥ 1 mg/ml solution in 20 mM NaH_2PO_4 0.15 M NaCl, 1.0% (w/v) mannitol, pH 7.4. Concentration determined by absorbance measurement at 280 nm and using an extinction coefficient of 1.4 ($\epsilon_{0.1\%}$).
Reconstitution:	Reconstitute with deionized water.
Storage:	Store lyophilized or reconstituted and aliquoted material at -20 °C for prolonged periods. Avoid freeze-thaw cycles. Alternatively, add 0.02% (w/v) sodium azide to reconstituted solution and store at 4 °C.
Country of origin:	USA
Size Options:	0.1 mg or 0.5 mg

Applications

Working Concentration:	Approximately 1-5 μ g/ml. Researcher should titer antibody in specific assay.
ELISA:	Binds immobilized human FVIII.
Immunoblotting:	Not recommended.
Inhibition:	Strongly inhibitory in aPTT clotting assay. ¹
Bio-layer interferometry:	Pairs with GMA-8011 and -8013.



References

- [1] S.L. Meeks, J.F. Healey, E.T. Parker, R.T. Barrow, P. Lollar. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. (2007). *Blood*. 110(13):4234-4242.
- [2] P.T. Nguyen, K.B. Lewis, R.A. Ettinger, J.T. Schuman, J.C. Lin, J.F. Healey, S.L. Meeks, P. Lollar, K.P. Pratt. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. (2014). *Blood*. 123(17):2732-2739.
- [3] N.C. Leksa, P.-L. Chiu, G.M. Bou-Assaf, C. Quan, Z. Liu, A.B. Goodman, M.G. Chambers, S.E. Tsutakawa, M. Hammel, R.T. Peters, T. Walz, J.D. Kulman. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein. (2017). *J Thromb Haemost*. 15(6): 1167-1179.
- [4] G.S. Pandey, C. Yanover, L.M. Miller-Jenkins, S. Garfield, S.A. Cole, J.E. Curran, E.K. Moses, N. Rydz, V. Simhadri, C. Kimchi-Sarfaty, D. Lillcrap, K. Viel, T.M. Przytycka, G. Pierce, T.E. Howard, Z.E. Sauna, the PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. (2013). *Nat Med*. 19(10):1318–1324.